GoFinsa

Welcome to GoFinsa!

Abbott Laboratories

ABT
109.93 USD
-3.23%
Session close supplied for

US market indices — session close

· US trading-session date · Points, not USD

Dow Jones Industrial Average

51,285.73 points

-237.33 points (-0.46%)

Nasdaq Composite

24,579.42 points

+264.43 points (+1.09%)

S&P 500

7,376.86 points

+23.13 points (+0.31%)

November 6, 2026 session closes reported by Associated Press and corroborated by Reuters; not live. Nasdaq means the Nasdaq Composite.

Abbott Laboratories stock (ABT) price and technical analysis

GoFinsa tracks Abbott Laboratories under symbol ABT, with the latest available price at 109.93 USD. This page includes multi-timeframe charts, technical analysis and related market news.

The session change is -3.23%.

Market data source: Dated supplied session quote · Latest available update: 2026-11-06 · Delayed market data

Abbott Laboratories (ABT) — Session close

· US trading-session date · USD

109.93 USD

Session change
-3.23%
Trading volume
8.35M shares
Relative volume
0.98×

Dated close values supplied for this session; not live prices or independently exchange-verified. K/M/B volume abbreviations preserve the source rounding.

Retained financial reference data

Previous record reference: 2026-10-27. These financial metrics were not recalculated or refreshed with the stock price.

Market capitalization (reference)
173.92 B USD
Trailing P/E (reference)
33.11
Trailing EPS (reference)
3.09 USD
Trailing dividend yield (reference)
2.38%
Sector
تكنولوجيا الصحة
Analyst view (reference)
شراء
Net margin (reference)
—
Return on equity (reference)
—

Retained technical reference data

Previous record reference: 2026-10-27. Not recomputed using the new close.

Technical rating: —RSI (14): —MACD: —CCI: —

Abbott Laboratories Stock (ABT): Price, Fundamentals and Risks

Company research · ABT

Understanding Abbott Laboratories (ABT)

This research briefing examines Abbott Laboratories (ABT), a company active in medical devices, diagnostics, nutrition and established medicines. Business quality and share valuation are distinct questions: even a durable company can trade at a price that assumes too much future growth. The market observations supplied for October 14, 2026 are treated as a dated research snapshot, not a live quote or a verified regular-session close. Investors should examine financial disclosures, strategy, execution and downside exposure before placing an order.

Reference quote and market session

The supplied reference price for ABT is $102.61, with a displayed change of +0.78%. This is user-provided reference information dated October 14, 2026, captured before the US regular session, not a live price or that session’s official close. Pre-market activity can involve different liquidity and spreads. A decision made later must rely on the executable bid/ask, the relevant session and updated company disclosures rather than treating this snapshot as a current trading signal.

Stock snapshot: market cap, trading volume and valuation

In the user-supplied market snapshot dated 14 October 2026, Abbott Laboratories carried a market capitalization of approximately $177.55 billion, displayed volume of 9,860,000 shares and relative volume of 1.06. The snapshot reported a P/E ratio of 33.17, trailing twelve-month EPS of $3.09, year-on-year EPS change of −61.31%, and indicated dividend yield of 2.44%. Its screening sector was تكنولوجيا الصحة. The snapshot analyst consensus read “Buy”; this is not a GoFinsa investment recommendation. These are dated, third-party reference figures rather than a live quote or official close, and calculation methods may differ from the issuer’s regulatory filings.

Business model and value creation

The operating model of Abbott Laboratories centers on medical devices, diagnostics, nutrition and established medicines. Investors should identify who pays the company, how prices are negotiated, which revenue streams recur, and which depend on discretionary or cyclical capital spending. Understanding customer switching costs and contract structures is more revealing than simply comparing the current quote with past highs. The durability of economic profit depends on where the company controls value in its supply or service chain.

Revenue quality and underlying demand

Revenue growth should be separated into underlying volume, realized pricing, product mix, acquisitions and currency impacts where relevant. For Abbott Laboratories, a particularly useful operating lens is monitor glucose monitoring demand, diagnostic testing and medical product pricing. Reported revenue gains can occur without matching improvement in cash collections or recurring demand. Comparing consistent reporting periods and management supporting disclosures can distinguish structural progress from temporary pricing or accounting effects.

Profitability and operating margins

Assess ABT through gross margin, operating margin and net earnings rather than one profit headline. Greater sales can coincide with lower unit economics if input costs rise, pricing power weakens, or the product mix changes. Likewise, one-time gains can lift net income without improving ordinary operations. A sound analysis reconciles earnings definitions and period dates, making explicit whether a figure describes the fiscal year, trailing twelve months or a single quarter.

Cash generation and capital allocation

Operating cash flow measures the cash consequences of business activity; free cash flow additionally reflects capital investment. A company engaged in medical devices, diagnostics, nutrition and established medicines may direct resources toward development, infrastructure, acquisitions, debt repayment and shareholder distributions. Cash conversion, working capital and financing needs matter because positive accounting profit does not, on its own, finance expansion. Compare multi-year results and distinguish unusual transactions from recurring spending.

Valuation relative to operations

No single valuation multiple proves ABT undervalued or overvalued. Market pricing embeds expectations for monitor glucose monitoring demand, diagnostic testing and medical product pricing and changes as the cost of capital shifts. The supplied trailing P/E display is 32.91; it is a dated metric whose earnings basis and reporting period need confirmation before interpretation. Compare multiple valuation approaches and genuinely relevant competitors, adjusting for growth, profitability, leverage and different accounting practices.

Company-specific growth catalysts

One company-specific driver to monitor is monitor glucose monitoring demand, diagnostic testing and medical product pricing. Evidence is stronger when operational improvements translate into repeatable revenue, durable margins and dependable cash generation. Product announcements, partnerships and strategic plans are not equivalent to recognized revenue. Follow deployment schedules, economic terms, customer adoption and management risk qualifications to determine whether a catalyst is material.

Industry position and competition

Abbott Laboratories competes within medical devices, diagnostics, nutrition and established medicines. Market position depends on technical capability, product quality, pricing, distribution, customer relationships and capital requirements in different combinations. An industry-wide expansion should not automatically be assigned to this company; its share gains, execution capacity and competitive intensity determine whether it captures value. In some markets, an attractive growth outlook can still coexist with deteriorating industry returns.

Operational and financial risks

Key exposures include healthcare regulation, reimbursement and manufacturing costs. Macro sensitivity, interest rates, foreign exchange and procurement conditions can amplify company-specific challenges. Effective risk assessment identifies the transmission mechanism: does the issue reduce demand, increase unit cost, delay customer payment or alter the balance sheet? That framing supports monitoring and scenario analysis more than a generic warning that equity markets can fluctuate.

Financial results and reference metrics

The supplied October 14, 2026 reference materials list market capitalization as ‪177.55 B‬ USD, fiscal-year revenue as ‪44.33 B‬ USD, and annual net income as ‪6.50 B‬ USD. Fiscal years differ across companies, while quote dashboards may mix fiscal figures with trailing periods. These are user-provided figures awaiting source-by-source reconciliation, not independently audited claims in this article. Confirm individual reporting dates and accounting labels before deriving growth rates or margins.

Dividends and shareholder returns

The indicated dividend yield in the supplied snapshot is 2.46%. A yield varies as the share price changes and does not guarantee a future payout. If the company does not pay a dividend, reinvestment and potential business appreciation may be more central to the investment case. For any payout policy, review declared dividends, share repurchases, leverage, cash flow coverage and competing capital needs.

Upside business scenario

An upside business case would require measurable progress in monitor glucose monitoring demand, diagnostic testing and medical product pricing, supported by disciplined costs, stronger cash generation and manageable balance-sheet risk. This is a conditional operating scenario, not a predicted price target. Shares can still decline following favorable earnings if investors had anticipated even stronger outcomes or if interest rates and risk appetite move against the sector.

Downside business scenario

The downside case involves healthcare regulation, reimbursement and manufacturing costs, potentially weakening volume, margins or returns on investment. A stretched valuation or elevated debt load can magnify market reactions. Investors should identify which disclosed metrics would invalidate their thesis rather than relying on a recent share-price peak, an analyst rating or their original purchase price. Scenario ranges are more useful than portraying any single future outcome as certain.

Investor research checklist

Before acting on ABT, review its latest annual and interim filings, verify the timestamp and session of the quote, compare consistent financial periods, and reconcile debt and free cash flow. Track monitor glucose monitoring demand, diagnostic testing and medical product pricing against healthcare regulation, reimbursement and manufacturing costs. Check whether the instrument is offered in your jurisdiction and under what fees and product terms; contracts for difference are not the same as direct share ownership and can entail significant losses.

Frequently asked questions about ABT

Q: What is the reference quote for ABT? A: $102.61, from the October 14, 2026 supplied snapshot—not a live price or the official close of that session.

Q: What merits special attention at Abbott Laboratories? A: monitor glucose monitoring demand, diagnostic testing and medical product pricing, along with earnings quality, cash generation and valuation.

Q: Does business growth guarantee a rising share price? A: No. Expectations, valuation and risks influence market returns.

Q: Are brokerage cards investment advice? A: No. They are identified sponsored information and trading carries risk.

Frequently asked questions about Abbott Laboratories (ABT)

What is the price of Abbott Laboratories (ABT)?

The latest price available in GoFinsa data is 109.93 USD. Price status may be live or delayed depending on the market and data provider.

What does the technical analysis for Abbott Laboratories (ABT) show?

There is currently insufficient data to produce technical analysis for this instrument.

What is the GoFinsa.com General Index for Abbott Laboratories?

The GoFinsa.com General Index is currently unavailable for this instrument.